Tag: AbSci

Protein printing company closes $10.4M Series D financing round

Protein printing company closes $10.4M Series D financing round

January 14, 2020 |

In Washington state, AbSci, the Protein Printing™ company with a best-in-class E. coli cell line for rapid and low-cost biomanufacturing of complex biotherapeutics, today announced the completion of a $10.4M Series D financing led by KBI Biopharma and JSR Life Sciences. Existing investors Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Columbia Ventures Corporation […]

Read More